Gastric acid secretion in the dog: A mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 29, Issue 4, 2002, Pages 365-382

  Äbelö, Angela ^a   Holstein, Björn ^a   Eriksson, Ulf G ^a   Gabrielsson, Johan ^a   Karlsson, Mats O ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

H+, K+ ATPase inhibitor; NONMEM; Omeprazole; PK PD modeling

Indexed keywords

HISTAMINE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; OMEPRAZOLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH ACID SECRETION; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; HISTAMINE RELEASE; PHYSIOLOGY; SECRETION; STOMACH ACID;

ANIMALS; DOGS; GASTRIC ACID; HISTAMINE; HISTAMINE RELEASE; MODELS, ANIMAL; MODELS, BIOLOGICAL; OMEPRAZOLE;

EID: 0036705109     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020905224001     Document Type: Article

References (24)

1. - on gastric acid secretion. Am. J. Physiol. 245:G64-71 (1983).
2. +)-ATPase by omeprazole in isolated vesicles requires proton transport. Biochim. Biophys. Acta 897:41-51 (1987).
3. +)-ATPase inhibitor depends upon the means of its activation. Biochem. Pharmacol. 36:339-344 (1987).
4. +-transporting ATPase: A new class of antisecretory agents. Trends Pharmacol. Sci. 14:323-325 (1993).
5. S. J. Hersey and G. Sachs. Gastric acid secretion. Physiol. Rev. 75: 155-189 (1995).
6. A. Äbelö, U. G. Eriksson, M. O. Karlsson, H. Larsson, and J. Gabrielsson. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J. Pharmacol. Exp. Ther. 295:662-669 (2000).
7. H. Larsson, M. L. Berglund, and E. Carlsson. Omeprazole - The relation between plasma levels and gastric antisecretory effect in the dog. Abstract, Acta Physiol. Scand. Suppl. 508:66 (1982).
8. H. Larsson, E. Carlsson, U. Junggren, L. Olbe, S.E. Sjöstränd, I. Skånberg, and G. Sundell. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterol. 85:900-907 (1983).
9. P. O. Lagerström and B. A. Persson. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. Chromatogr. 309: 347-356 (1984).
10. B. N. Halpern, T. Neveu, and C. W. M. Wilson. The distribution and fate of radioactive histamine in the rat. J. Physiol. 147:437-449 (1959).
11. S. L. Beal and L. B. Sheiner. NONMEM Users Guide, NONMEM Project Group, University of California, San Francisco, 1992.
12. E. N. Jonsson and M. O. Karlsson. Xpose - An S-Plus based population pharmacokinetic/ pharamacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58(1):51-64 (1999).
13. D. R. Scott, H. F. Helander, S. J. Hersey, and G. Sachs. The site of acid secretion in the mammalian parietal cell. Biochim. Biophys. Acta 1146:73-80 (1993).
14. J. De Graef and M. C. Woussen-Colle. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterol. 91:333-337 (1986).
15. K. Gedda, D. Scott, M. Besancon, and G. Sachs. The half life of the H, K ATPase of gastric mucosa. Gastroenterol. 109:1134-1141 (1995).
16. + ATPase. Annu. Rev. Pharmacol. Toxicol. 35:277-305 (1995).
17. T. Lind, C. Cederberg, G. Ekenved, U. Haglund, and L. Olbe. Effect of omeprazole - A gastric proton pump inhibitor - On pentagastrin stimulated acid secretion in man. Gut 24:270-276 (1983).
18. P. Olsson Gisleskog, D. Hermann, M. Hammarlund-Udenaes, and M. O. Karlsson. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin. Pharmacol. Ther. 64:636-647 (1998).
19. M. Hassan, U. S. H. Svensson, P. Ljungman, B. Björkstrand, H. Olsson, M. Bielenstein, M. Abdel-Rehim, C. Nilsson, M. Johansson, and M. O. Karlsson. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br. J. Clin. Pharmacol. 48:669-677 (1999).
20. V. I. Avramis, S. Sencer, A. P. Periclou, H. Sather, B. C. Bostrom, L. J. Cohen, A. G. Ettinger, L. J. Ettinger, J. Franklin, P. S. Gaynon, J. M. Hilden, B. Lange, F. Majlessipour, P. Mathew, M. Needle, J. Neglia, G. Reaman, and J. S. Holcenberg. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99:1986-1994 (2002).
21. M. Katashima, K. Yamamoto, Y. Tokuma, T. Hata, Y. Sawada, and T. Iga. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole, lansoprazole and pantoprazole, in humans. Eur. J. Drug. Metab. Pharmacokinet. 23:19-26 (1998).
22. T. Rydberg, A. Jonsson, M. O. Karlsson, and A. Melander. Concentration-effect relations of glibenclamide and its active metabolites in man: Modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 43(4):373-378 (1997).
23. E. N. Jonsson, J. R. Wade, and M. O. Karlsson. Nonlinearity detection: Advantages of nonlinear mixed effects modelling. AAPS Pharmsci. 2(3) article 32 (2000).
24. B. K. Kataria, S. A. Ved, H. F. Nicodemus, G. R. Hoy, D. Lea, M. Y. Dubois, J. W. Mandema, and S. L. Shafer. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology. 80(1):104-122 (1994).